An intact C-terminal end of albumin is required for its long half-life in humans

Albumin has an average plasma half-life of three weeks and is thus an attractive carrier to improve the pharmacokinetics of fused therapeutics. The half-life is regulated by FcRn, a cellular receptor that protects against intracellular degradation. To tailor-design the therapeutic use of albumin, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsen, Jeannette, Trabjerg, Esben, Grevys, Algirdas, Azevedo, Claudia, Brennan, Stephen O., Stensland, Maria, Wilson, John, Sand, Kine Marita Knudsen, Bern, Malin, Dalhus, Bjørn, Roopenian, Derry C., Sandlie, Inger, Rand, Kasper Dyrberg, Andersen, Jan Terje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171077/
https://www.ncbi.nlm.nih.gov/pubmed/32313072
http://dx.doi.org/10.1038/s42003-020-0903-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171077/
https://www.ncbi.nlm.nih.gov/pubmed/32313072
http://dx.doi.org/10.1038/s42003-020-0903-7

Ejemplares similares